Equity Overview
Price & Market Data
Price: $0.353
Daily Change: -$0.0021 / 0.59%
Range: $0.34 - $0.356
Market Cap: $436,280,192
Volume: 598,653
Performance Metrics
1 Week: -3.31%
1 Month: -0.57%
3 Months: 33.33%
6 Months: 197.4%
1 Year: 128.3%
YTD: 183.8%
Company Details
Employees: 9
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.